Swiss pharmaceutical and diagnostics giant Roche announced the success of a pivotal clinical trial for its drug divarasib in the treatment of a form of lung cancer.
The researchers did not identify any new adverse effects in patients taking the experimental drug.
Keystone-SDA
On Thursday, the Swiss pharmaceutical and diagnostics giant Roche announced the success of a pivotal clinical trial for its drug divarasib in the treatment of a form of lung cancer as a second-line therapy.
This content was published on
July 2, 2026 - 10:12
The Phase 3 trial compared Roche’s divarasib with treatments sold by Amgen and Bristol Myers in patients with non-small cell lung…
Roche’s lung cancer drug candidate divarasib has beaten marketed drugs from Amgen and Bristol Myers Squibb in a head-to-head…
(Bloomberg) -- Roche Holding AG’s experimental lung cancer pill outperformed two approved medicines in a late-stage study,…
Back in March, Roche revealed that its breast cancer pill had failed in a pivotal Phase 3 trial. Data presented at ASCO reveal…
To Roche, a phase 3 flop in first-line breast cancer does not erase the megablockbuster potential of its oral SERD drug…
D3 Bio Presents First-Line Data for Elisrasib (D3S-001) at ASCO 2026; Next-Generation KRAS G12C Inhibitor Shows Landmark Efficacy…
Roche KRAS drug succeeds in head-to-head lung cancer study
Roche’s lung cancer pill beats rivals in head-to-head Phase 3 study
Revolution Medicines shares promising data around KRAS drug combination
Arovella prepares off-the-shelf cancer trial after boardroom shakeup
Roche drug sets new standard for KRAS-driven lung cancer
